ReviewBiosensors2018
Autoantibodies as Potential Biomarkers in Breast Cancer.
Review in Biosensors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.Frontiers in immunology · 2024Pooled it
- Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection.BMC cancer · 2022Pooled it
- Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis.Scientific reports · 2021Trial
- The early diagnostic value of lung cancer autoantibodies and tumor markers in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Exploring the significance of IgM expression in the lymphatic system during breast cancer progression.Translational cancer research · 2026Article
- Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host.Frontiers in immunology · 2026Review
- Correlation of Anti-TULP1 Autoantibodies with Breast Cancer and Autoimmune Retinopathy.International journal of molecular sciences · 2025Article
- Use and Comparison of Machine Learning Techniques to Discern the Protein Patterns of Autoantibodies Present in Women with and without Breast Pathology.Journal of proteome research · 2025Article
- Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women.Biomolecules · 2023Article
- The RELT Family of Proteins: An Increasing Awareness of Their Importance for Cancer, the Immune System, and Development.Biomedicines · 2023Review
- Autoantibody Diversity Is Augmented in Women with Breast Cancer and Is Related to the Stage of the Disease.Current oncology (Toronto, Ont.) · 2023Article
- In silico designing and expression of novel recombinant construct containing the variable part of CD44 extracellular domain for prediagnostic breast cancer.Cancer reports (Hoboken, N.J.) · 2023Article
- Early detection of lung cancer in a real-world cohortFrontiers in oncology · 2023Article
- Diagnostic value of tumor-associated autoantibodies panel in combination with traditional tumor markers for lung cancer.Frontiers in oncology · 2023Article
- Development and validation of machine learning-based risk prediction models of oral squamous cell carcinoma using salivary autoantibody biomarkers.BMC oral health · 2022Article
- Article
- Review
- Article
- Evaluating a Panel of Autoantibodies Against Tumor-Associated Antigens in Human Osteosarcoma.Frontiers in genetics · 2022Article
- Serum anti-SERPINE1 antibody as a potential biomarker of acute cerebral infarction.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a major cause of mortality in women; however, technologies for early stage screening and diagnosis (e.g., mammography and other imaging technologies) are not optimal for the accurate detection of cancer. This creates demand for a more effective diagnostic means to replace or be complementary to existing technologies for early discovery of breast cancer. Cancer neoantigens could reflect tumorigenesis, but they are hardly detectable at the early stage. Autoantibodies, however, are biologically amplified and hence may be measurable early on, making them promising biomarkers to discriminate breast cancer from healthy tissue accurately. In this review, we summarized the recent findings of breast cancer specific antigens and autoantibodies, which may be useful in early detection, disease stratification, and monitoring of treatment responses of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.